Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained a drug registration certificate.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced recently that its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. has received the "Drug Registration Certificate" for complex amino acids (16AA)/glucose (12.6%) electrolyte injection issued by the National Medical Products Administration (NMPA). This product is the first generic in China to be approved through the evaluation of generic drug quality and efficacy consistency.